In addition to TMZ, Bevacizumab, a humanized monoclonal antibody approved by Food and Drug Administration (FDA) in glioma therapy, acts as an anti-angiogenic moiety that efficiently interferes with ectopic tumor vasculature by down-regulating the expression of the vascular endothelial growth factor (VEGF-A) [19]. Here, VEGFA is linked to neoplasm.